Demonstrates improved risk stratification in acute myeloid leukemia by integrating FLT3-ITD features with clinical factors, suggesting better outcomes for high-risk patients.
Key Points
The research investigates the prognostic value of FLT3-ITD molecular features along with clinical risk factors in acute myeloid leukemia.
Analyzed FLT3-ITD mutations using next-generation sequencing in 170 newly diagnosed AML patients.
Evaluated relationships between insertion characteristics and overall survival alongside clinical factors like white blood cell count.
Assessed the effectiveness of early transplantation and FLT3 inhibitor therapy on survival outcomes.
FLT3-ITD patients with longer insertion lengths and higher allelic ratios showed shorter overall survival.
Early FLT3 inhibitor therapy significantly improved overall survival, especially in patients with HR/β1 insertions.
White blood cell counts above 30 × 10⁹/L indicated a higher risk of shorter survival.